Slingshot members are tracking this event:

AstraZeneca (AZN) Announces Phase 3 SOLO-2 Results Assessing Lynparza in Treatment-Resistant Ovarian Cancer

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 26, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 3, Solo-2, Lynparza, Treatment-resistant, Ovarian Cancer, Platinum-resistant Ovarian Cancer, Brca Mutation-positive